ICSBP Antibody (B-4): sc-393676

ICSBP Antibody (B-4) is a mouse monoclonal IgG1 antibody that detects ICSBP (Interferon consensus sequence-binding protein, also known as Interferon regulatory factor 8; IRF-8) in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). ICSBP plays a crucial role as a transcription factor in the regulation of immune responses, particularly in the signaling pathways mediated by interferon-gamma (IFN-γ) during the differentiation of dendritic cells and macrophages. The importance of ICSBP lies in modulating TLR (Toll-like receptor) signaling through physical interaction with TRAF6, which occurs between amino acid residues 356 and 305. This interaction enhances the cross-talk between IFN-γ and TLR pathways and contributes to the overall immune response. ICSBP antagonizes the oncogenic Bcr/Abl fusion protein by downregulating Bcl-2, thereby influencing cell survival and apoptosis. As a member of the interferon regulatory factor family, which includes IRF-1, IRF-2, and ISGF-3, ICSBP contains a conserved DNA-binding domain in its N-terminal region and a regulatory domain in its C-terminal region, allowing binding to the interferon-stimulated response element (ISRE) and regulation of IFN-α and IFN-β expression. Anti-ICSBP antibody (B-4) serves as an essential tool for researchers studying immune regulation and the molecular mechanisms underlying various immune responses.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

ICSBP Antibody (B-4) References:

1. Essential role for ICSBP in the in vivo development of murine CD8alpha + dendritic cells.  |  Aliberti, J., et al. 2003. Blood. 101: 305-10. PMID: 12393690
2. IRF-8/ICSBP and IRF-1 cooperatively stimulate mouse IL-12 promoter activity in macrophages.  |  Masumi, A., et al. 2002. FEBS Lett. 531: 348-53. PMID: 12417340
3. Retroviral integration site analysis identifies ICSBP as a collaborating tumor suppressor gene in NUP98-TOP1-induced leukemia.  |  Gurevich, RM., et al. 2006. Exp Hematol. 34: 1192-201. PMID: 16939812
4. Acceleration of chronic myeloproliferation by enforced expression of Meis1 or Meis3 in Icsbp-deficient bone marrow cells.  |  Hara, T., et al. 2008. Oncogene. 27: 3865-9. PMID: 18223676
5. Constitutive activation of SHP2 in mice cooperates with ICSBP deficiency to accelerate progression to acute myeloid leukemia.  |  Konieczna, I., et al. 2008. J Clin Invest. 118: 853-67. PMID: 18246201
6. Epigenetic silencing of the interferon regulatory factor ICSBP/IRF8 in human multiple myeloma.  |  Tshuikina, M., et al. 2008. Exp Hematol. 36: 1673-1681. PMID: 18922617
7. Interferon consensus sequence binding protein (ICSBP) decreases beta-catenin activity in myeloid cells by repressing GAS2 transcription.  |  Huang, W., et al. 2010. Mol Cell Biol. 30: 4575-94. PMID: 20679491
8. Functional domain analysis of interferon consensus sequence binding protein (ICSBP) and its association with interferon regulatory factors.  |  Sharf, R., et al. 1995. J Biol Chem. 270: 13063-9. PMID: 7768900
9. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene.  |  Holtschke, T., et al. 1996. Cell. 87: 307-17. PMID: 8861914
10. Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias.  |  Schmidt, M., et al. 1998. Blood. 91: 22-9. PMID: 9414265

The preferred ICSBP antibody is ICSBP Antibody (E-9): sc-365042.